BioSpace News Archive

Genetown

Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced positive interim results from the ongoing Phase 1 study of zilebesiran, an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen in development for the treatment of hypertension.

November 13, 2021
·
13 min read
Drug Development

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

Outlook Therapeutics, Inc. presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration and other retinal indications, at the Retinal Subspecialty Day, AAO 2021 Annual Conference.

November 13, 2021
·
7 min read